CTX130

CTX130 is a first-in-class, allogeneic, gene-edited chimeric antigen receptor (CAR) T cell therapy developed using CRISPR/Cas9 technology. It is designed to target the CD70 antigen, which is expressed on various tumor cells including those in T-cell lymphomas and renal cell carcinoma. The therapy uses healthy donor-derived T cells that are genetically modified to express an anti-CD70 CAR and to disrupt the TRAC and β2-microglobulin (β2M) genes, reducing risks of graft-versus-host disease and immune rejection. Additionally, endogenous CD70 expression is disrupted to prevent fratricide among therapeutic cells. CTX130 has shown promising safety and efficacy in early-phase clinical trials for relapsed or refractory T-cell malignancies and advanced clear cell renal cell carcinoma[1][5][6][7].

Other names

Allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD70 antigen